Aptar partnership to speed FDA approval

CRYSTAL LAKE - Aptar Pharma said it has formed a new partnership aimed at speeding FDA approval of orally inhaled and nasal drug products.

Nanopharm, an Aptar company and leader in contract research and development services for those drug products, announced an exclusive collaboration with Fluidda. That company is a leader in the field of Functional Respiratory Imaging.

The companies will leverage their respective proprietary technology platforms to help accelerate U.S. Food and Drug Administration approvals for orally inhaled generic products. Nanopharm was acquired by Aptar in 2019 as part of the company's strategy to expand its service offerings and partner with pharmaceutical companies earlier in the drug development process.

Nanopharm has pioneered the development of generic drugs to be inhaled for asthma and Chronic Obstructive Pulmonary Disease (COPD).

"We are pleased to solidify our relationship with Fluidda and its world-leading FRI technology. A company would have to spend several years to achieve the current combined expertise and experience of Nanopharm and Fluidda. The collaboration between Nanopharm and Fluidda has the potential to revolutionize this arduous regulatory pathway," said Dr. Jag Shur, vice president, Science & Technology at Nanopharm.